Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026
Gilead Sciences reported Q2 CY2026 results. Revenue rose 10.2% year on year to $7.80 billion and exceeded Wall Street estimates by 6.2%, according to the company. Full-year revenue guidance was $30.25 billion at the midpoint, 0.6% below analysts’ estimates. Non-GAAP adjusted EPS was a loss of $6.75, beating consensus by 6.9%.
How this was made
The 30-second read
Why it matters
The key trade tension is a Q2 revenue and EPS beat versus a slightly light full-year revenue guidance midpoint, alongside large non-GAAP margin and EPS deterioration year over year.
Market read
This is a company-specific earnings/guidance update with enough detail to reprice near-term expectations around revenue trajectory and profitability.
What to watch
The article highlights severe non-GAAP margin/EPS deterioration year over year; traders may need to assess whether this is one-off (tax/interest) versus structural cost pressure.
Background
Gilead Sciences is a biopharmaceutical company focused on HIV and other viral diseases, with quarterly results used to gauge demand and profitability trends.
Ticker impact
Gilead reported Q2 CY2026 revenue of $7.80B (+10.2% YoY) and guided full-year revenue to $30.25B midpoint, slightly below estimates.
Near-term trading likely hinges on whether investors focus more on the revenue beat and EPS beat versus the full-year revenue guide miss and margin/EPS deterioration.
The article provides concrete quarterly results (revenue beat, EPS beat) plus a specific full-year revenue guidance miss and large margin/EPS contraction, which can offset each other in the market’s reaction.
Market effects
Signals continued volatility in profitability/margins for large-cap biopharma, even when top-line growth is resilient.
Limited, primarily affects US large-cap healthcare sentiment rather than broad regional flows.
Low, the disclosed facts are company-specific and do not indicate cross-border regulatory or supply shocks.
Counterpoint
Investors may treat the full-year revenue guide miss as minor (0.6% below) and overweight the Q2 revenue outperformance and EPS beat.
Key entities
- companyGilead Sciences
Reported Q2 CY2026 results and provided full-year revenue and EPS outlook.
